TOVX Theriva Biologics Inc
Price (delayed)
$1.18
Market cap
$3.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$19.03
Enterprise value
-$6.86M
Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's
Highlights
Theriva Biologics's EPS has increased by 43% from the previous quarter and by 33% YoY
The debt has declined by 27% year-on-year and by 10% since the previous quarter
The net income has decreased by 40% YoY but it has increased by 3.9% QoQ
The quick ratio has plunged by 55% YoY and by 32% from the previous quarter
TOVX's equity is down by 48% YoY and by 23% from the previous quarter
Key stats
What are the main financial stats of TOVX
Market
Valuations
Earnings
Shares outstanding
2.78M
Market cap
$3.28M
Enterprise value
-$6.86M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.17
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$26.35M
Net income
-$25.65M
EBIT
-$25.65M
EBITDA
-$25.06M
Free cash flow
-$16.94M
Per share
Balance sheet
Liquidity
EPS
-$19.03
EPS diluted
-$19.03
Free cash flow per share
-$12.56
Book value per share
$6.85
Revenue per share
$0
TBVPS
$26.22
Total assets
$35.35M
Total liabilities
$16.29M
Debt
$1.57M
Equity
$19.07M
Working capital
$8.7M
Debt to equity
0.08
Current ratio
2.15
Quick ratio
1.54
Net debt/EBITDA
0.4
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-61.6%
Return on equity
-101.6%
Return on invested capital
-135.6%
Return on capital employed
-92.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TOVX stock price
How has the Theriva Biologics stock price performed over time
Intraday
5.36%
1 week
-1.67%
1 month
-18.06%
1 year
-89.27%
YTD
-32.57%
QTD
7.27%
Financial performance
How have Theriva Biologics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$26.35M
Net income
-$25.65M
Gross margin
N/A
Net margin
N/A
The net income has decreased by 40% YoY but it has increased by 3.9% QoQ
The company's operating income fell by 23% YoY but it rose by 6% QoQ
Growth
What is Theriva Biologics's growth rate over time
Valuation
What is Theriva Biologics stock price valuation
P/E
N/A
P/B
0.17
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Theriva Biologics's EPS has increased by 43% from the previous quarter and by 33% YoY
TOVX's P/B is 60% below its 5-year quarterly average of 0.4 and 20% below its last 4 quarters average of 0.2
TOVX's equity is down by 48% YoY and by 23% from the previous quarter
Efficiency
How efficient is Theriva Biologics business performance
The ROE has shrunk by 137% YoY and by 13% QoQ
The ROA has plunged by 110% YoY and by 8% from the previous quarter
The return on invested capital has declined by 33% year-on-year
Dividends
What is TOVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TOVX.
Financial health
How did Theriva Biologics financials performed over time
The total assets is 117% more than the total liabilities
The quick ratio has plunged by 55% YoY and by 32% from the previous quarter
Theriva Biologics's current ratio has decreased by 47% YoY and by 19% from the previous quarter
The debt is 92% smaller than the equity
TOVX's equity is down by 48% YoY and by 23% from the previous quarter
The debt to equity has grown by 33% YoY and by 14% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.